Sort
30,917 grants matching “tumor microenvironment”
INTERCELLULAR COMMUNICATION AND THE RADIATION-INDUCED BYSTANDER EFFECT
$425,040Edouard I Azzam · Columbia University Health Sciences · P01 · FY2012 · CA
Mechanisms for Salivary Tumor Epithelial-Mesenchymal Transitions
$425,002David K Ann · Beckman Research Institute/City Of Hope · R01 · FY2019 · DE
Mechanisms for Salivary Tumor Epithelial-Mesenchymal Transitions
$425,002David K Ann · Beckman Research Institute/City Of Hope · R01 · FY2016 · DE
Mechanisms for Salivary Tumor Epithelial-Mesenchymal Transitions
$425,002David K Ann · Beckman Research Institute/City Of Hope · R01 · FY2020 · DE
Mechanisms for Salivary Tumor Epithelial-Mesenchymal Transitions
$425,002David K Ann · Beckman Research Institute/City Of Hope · R01 · FY2017 · DE
Mechanisms for Salivary Tumor Epithelial-Mesenchymal Transitions
$425,002David K Ann · Beckman Research Institute/City Of Hope · R01 · FY2018 · DE
Role of Hedgehog Signaling in JAK2V617F Associated Myelofibrosis
$425,000Akil Merchant · Cedars-Sinai Medical Center · R01 · FY2021 · HL
Role of Hedgehog Signaling in JAK2V617F Associated Myelofibrosis
$425,000Akil Merchant · Cedars-Sinai Medical Center · R01 · FY2020 · HL
Role of Hedgehog Signaling in JAK2V617F Associated Myelofibrosis
$425,000Akil Merchant · Cedars-Sinai Medical Center · R01 · FY2019 · HL
Regulation of the neuroinflammatory response in autoimmune uveitis
$425,000Bruce R Ksander · Massachusetts Eye And Ear Infirmary · R01 · FY2021 · EY
Role of Hedgehog Signaling in JAK2V617F Associated Myelofibrosis
$425,000Akil Merchant · Cedars-Sinai Medical Center · R01 · FY2022 · HL
The Role of Cidofovir and Structural Analogs as Adjuvant Therapy for Glioblastoma
$424,977Charles S Cobbs · Swedish Medical Center, First Hill · R01 · FY2017 · CA
Investigation of novel signaling protein in 3D and in vivo PDAC models using second generation Ref-1 inhibitors
$424,794Melissa L Fishel · Indiana University Indianapolis · R01 · FY2022 · CA
Investigation of novel signaling protein in 3D and in vivo PDAC models using second generation Ref-1 inhibitors
$424,794Melissa L Fishel · Indiana University Indianapolis · R01 · FY2023 · CA
Reprogramming the pancreatic tumor microenvironment with immunotherapy
$424,612Lei Zheng · Johns Hopkins University · R01 · FY2016 · CA
Reprogramming the pancreatic tumor microenvironment with immunotherapy
$424,612Lei Zheng · Johns Hopkins University · R01 · FY2015 · CA
The role of PCDH7 in lung cancer pathogenesis
$424,551Kathryn Ann O'Donnell · Ut Southwestern Medical Center · R01 · FY2021 · CA
The role of PCDH7 in lung cancer pathogenesis
$424,551Kathryn Ann O'Donnell · Ut Southwestern Medical Center · R01 · FY2020 · CA
PAI-1-mediated early-onset endometrial cancer
$424,546Nameer Kirma · University Of Texas Hlth Science Center · R01 · FY2024 · CA
Membrane protein target for leukemia therapy
$424,411Xunlei Kang · University Of Missouri-Columbia · R37 · FY2024 · CA
Immune activation by necroptotic cell death
$424,373Andrew Atwell Oberst · University Of Washington · R01 · FY2021 · CA
Collaborative Innate-Adaptive Immune Regulation of Tumor Progression
$424,356Matthew F Krummel · University Of California, San Francisco · U01 · FY2010 · CA
Sculpting the atherosclerotic plaque by neurotrophins
$424,264Barbara L Hempstead · Weill Medical Coll Of Cornell Univ · P01 · FY2007 · HL
Epigenetically regulated stemness program and stem cell niche as targets in pediatric DIPG
$424,220Stefanie Galban · University Of Michigan At Ann Arbor · R01 · FY2024 · NS
Targeted MEK inhibition to enhance immunotherapy in cholangiocarcinoma
$424,213Gregory B. Lesinski · Emory University · R01 · FY2020 · CA